Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into an exclusive Distribution Agreement with Er-Kim, a leading partner for biotech companies in international markets, for the oral and intravenous formulations of XENLETA
